Paul Lemieux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Lemieux has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Giada Maria Di Pietro
University of Milan, Milan, Italy
1 shared publication - Massimo Luca Castellazzi
Pediatric Emergency Department, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
1 shared publication - Paola Marchisio
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, 20122 Milano, Italy
1 shared publication - Pietro Bosi
Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy
1 shared publication
Latest Publications
- Open Access
Group A Streptococcal Infections in Pediatric Age: Updates about a Re-Emerging Pathogen
Group A Streptococcus (GAS) presents a significant global health burden due to its diverse clinical manifestations ranging from mild infections to life-threatening invasive diseases. While historically stable, the incidence of GAS infections declined during the COVID-19 pandemic but resurged following the relaxation of preventive measures. Despite general responsiveness to β-lactam antibiotics, there remains an urgent need for a GAS vaccine due to its substantial global disease burden, particularly in low-resource settings. Vaccine development faces numerous challenges, including the extensive strain diversity, the lack of suitable animal models for testing, potential autoimmune complications, and the need for global distribution, while addressing socioeconomic disparities in vaccine access. Several vaccine candidates are in various stages of development, offering hope for effective prevention strategies in the future.
Open AccessGroup A Streptococcal Infections in Pediatric Age: Updates about a Re-Emerging Pathogen
Group A Streptococcus (GAS) presents a significant global health burden due to its diverse clinical manifestations ranging from mild infections to life-threatening invasive diseases. While historically stable, the incidence of GAS infections declined during the COVID-19 pandemic but resurged following the relaxation of preventive measures. Despite general responsiveness to β-lactam antibiotics, there remains an urgent need for a GAS vaccine due to its substantial global disease burden, particularly in low-resource settings. Vaccine development faces numerous challenges, including the extensive strain diversity, the lack of suitable animal models for testing, potential autoimmune complications, and the need for global distribution, while addressing socioeconomic disparities in vaccine access. Several vaccine candidates are in various stages of development, offering hope for effective prevention strategies in the future.